Morgan Stanley Maintains Equal-Weight Rating for Insulet: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Morgan Stanley has maintained its Equal-Weight rating for Insulet (NASDAQ:PODD) but lowered its price target from $343.00 to $208.00. Insulet's shares are currently trading at $188.51, down 0.01% over the last 24 hours. A move to the new price target would represent a 10.34% increase from the current share price.
August 24, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley has maintained its Equal-Weight rating for Insulet but lowered its price target. This could potentially lead to a short-term increase in the stock price if the market aligns with this new target.
The lowering of the price target by Morgan Stanley could be seen as a negative signal, however, the current trading price is below the new target. If the market aligns with this new target, it could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100